U.S. markets close in 4 hours 52 minutes
  • S&P 500

    3,824.48
    +4.76 (+0.12%)
     
  • Dow 30

    31,313.24
    +43.15 (+0.14%)
     
  • Nasdaq

    12,983.72
    -14.03 (-0.11%)
     
  • Russell 2000

    2,187.53
    -20.26 (-0.92%)
     
  • Crude Oil

    64.30
    +3.02 (+4.93%)
     
  • Gold

    1,717.20
    +1.40 (+0.08%)
     
  • Silver

    26.25
    -0.14 (-0.52%)
     
  • EUR/USD

    1.2044
    -0.0023 (-0.19%)
     
  • 10-Yr Bond

    1.4620
    -0.0080 (-0.54%)
     
  • GBP/USD

    1.3982
    +0.0030 (+0.21%)
     
  • USD/JPY

    107.5850
    +0.5830 (+0.54%)
     
  • BTC-USD

    49,659.73
    -1,334.69 (-2.62%)
     
  • CMC Crypto 200

    994.71
    +7.51 (+0.76%)
     
  • FTSE 100

    6,642.39
    -33.08 (-0.50%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Rosen Law Firm Announces an Investigation of Securities Claims Against Homology Medicines, Inc. – FIXX

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX) resulting from allegations that Homology may have issued materially misleading business information to the investing public.

On July 21, 2020, Mariner Research ("Mariner") published a report questioning statements by Homology and its officers about the efficacy of HMI-102, the Company’s lead product candidate for treatment of phenylketonuria. Mariner focused on Homology’s HMI-102 dose escalation pheNIX trial, concluding that the Company concealed data showing HMI-102’s lack of efficacy and indicating that the program was unlikely to proceed to commercialization. Among other evidence, Mariner cited an email from Homology’s Chief Communications Officer appearing to indicate the Company’s awareness that a HMI-102 high dose patient had adverted to the adverse efficacy issue in a social media post during April 2020.

On this news, Homology’s stock price fell $1.71 per share, or 10.38%, over the following three trading days, closing at $14.77 per share on July 24, 2020.

Rosen Law Firm is preparing a securities lawsuit on behalf of Homology shareholders. If you purchased securities of Homology please visit the firm’s website at http://www.rosenlegal.com/cases-register-1968.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005835/en/

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com